Abstract
At the 2016 ASCO annual meeting, new data from two randomized phaseIII studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented. The focus is on the clinical impact of these data. Agroup of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data. The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC. Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of apatient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
